In a review of 83 eligible studies, researchers found little evidence to support the efficacy of cannabinoids to treat depressive disorders, anxiety disorders, or several other mental health disorders.
This article will evaluate and assess medical marijuana, also called medical cannabis, and will cover benefits and risks, clinical considerations affecting its recommendation, and currently available evidence.
In a review of 83 eligible studies, researchers found little evidence to support the efficacy of cannabinoids to treat depressive disorders, anxiety disorders, or several other mental health disorders. There is low-grade evidence that pharmaceutical cannabis may help improve symptoms of anxiety in patients with a comorbid medical condition.
The expansion of the sanctioned use of marijuana for recreational and medical purposes has exploded in recent years and warrants a critical appraisal of the primary care physician’s role in providing advice to and counseling patients.
Understanding the potential reactions that can occur from cannabis and synthetic cannabinoids can help emergency physicians recognize these effects in patients who may present to the emergency department.
A group of investigators posing as pregnant patients called marijuana dispensaries in Colorado to determine whether the stores’ staff recommended it for nausea and vomiting, if there were risks in pregnancy, and if providers should be consulted. The results were enlightening.
Perhaps no topic is more controversial than the use of marijuana in clinical practice. Within the United States, there are an estimated 55 million recent active users, defined as one to two uses within the previous year, and 35 million regular users, defined as one to two uses per month.